Royalty dispute settled between Apple and Qualcomm with Patent Settlement Agreement
Agreeing to a conclusion and finding a way out is the REAL deal breaker in Industry 4.0. Recently, technology entities Apple and Qualcomm settled their ongoing dispute on the clause of what Royalty amount should be paid for the technology utilised. Intellectual property assets is the real deal and after signing the settlement agreement the market share pricing of Qualcomm jumped by 16 percent and Apple share also saw marginal improvement.
Intellectual property assets is the real deal.
What one can infer and learn for this dispute is finding a middle path is the KEY to attain WIN-WIN situation for both technology driven companies who are pioneers in manufacturing and doing research in modem chips that connect smartphones to wireless data networks.
Finding a middle path is the KEY to attain WIN-WIN situation.
According to business standard article “Qualcomm alleged that Apple used its heft in the electronics business to wrongly order contract factories such as Hon Hai Precision Co Ltd’s Foxconn to withhold royalty payments from Qualcomm that Apple had historically reimbursed to the factories.”
About Technology Savvy Author:
International Speaker speaking on Strategic Aspects of amalgamating technology, law and business in Industry 4 Spectrum Era. Active speaker at tech global conferences and actively participate in ITU Regulatory Workshops & Initiatives on SDGs. Problem SOLVER & Business Strategist with 13+ yrs exp.
Seasoned Patent Strategist with expertise in IP portfolio research, cross-border tech transactions, licensing agreements, product clearance, FTO opinion, patent infringement & invalidity, IPR R&D Consultancy.
Core practice: IP harvesting, patent drafting, patent searches, PCT National phase patent prosecution in India (drafting office action responses for USPTO, EPO, UKIPO) & International trademark registration in India under Madrid Protocol.
Technical expertise: Bitcoin, Blockchain, Bigdata, Internet of Things (IoT), AI, ML, Software, Hardware, Therapeutic biologics, Agri biotech, Biosimilar drug, Plant Variety, Mechanical inventions, Electrical, Medical devices & Healthcare.
Go-to patent strategist for all time zones, be it new product launch in Asia, IP landscape across EU, freedom-to-operate analysis in Japan or patent invalidation for litigation in US.
Senior executive profile with featured publications: BBC World, Nature Group (Nature Reviews Drug Discovery), BusinessWorld, BioSpectrum Asia etc.
Previous work experience with US Law Firm headquartered in Greater New York City Area.
Engagement models: Hourly, project based, contractual consulting & monthly retainer.
Have successfully executed projects of every size in domain of pharmaceuticals, stents, diagnostic assays, computational, vaccines, antibodies, food enzymes, & cancer therapy.
IP counselling, legal advice & intersecting IP with competition laws, innovation, market-entry strategy & competitive intelligence.
For business advice, schedule a consultation: Connect and Share